Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Anatara Lifesciences Ltd ( (AU:ANR) ) has shared an update.
Anatara Lifesciences Ltd has completed Stage 2 of its GaRP-IBS Phase II trial, revealing positive trends in symptomatic relief for pain and abdominal distension, although the primary endpoint of statistical significance in IBS-SSS reduction was not achieved. The trial’s secondary endpoint showed significant improvement in anxiety scores, and the company is considering potential commercial discussions based on these outcomes.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focusing on significant unmet needs in human health, particularly conditions involving the gastrointestinal tract (GIT).
Average Trading Volume: 2,597,358
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.28M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.